
Congress on the Brink of Disrupting the PBM Market
During much of 2024, the prevailing view in Washington was that some policies related to pharmacy benefit managers (PBMs) would be included in the end-of-year continuing resolution.
During much of 2024, the prevailing view in Washington was that some policies related to pharmacy benefit managers (PBMs) would be included in the end-of-year continuing resolution.
In a new report, MGA examines the role of rebates among a subset of prescription drugs with the biggest price hikes between 2018 and 2023.
Provider networks are a well-known tool health insurance companies use to keep down the cost of care.
In December, MGA CEO Alex Brill participated in a RealClearPolitics event looking at the negative consequences of limiting the business practices of PBMs.
MGA latest white paper, by CEO Alex Brill, looks at the role of pharmacy benefit managers (PBMs) in the US prescription drug market.